Skip to main content

Tobin James R's Form 4 filing

Globus Medical Inc (GMED) · filed Mar 10, 2022

Accession no.
0001209191-22-018065
Filed
Mar 10, 2022
Trade date
Mar 8-10, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.02M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Tobin James RCIK 0001190128Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 8, 2022Class A Common StockMOption exerciseAcquired+4,484$43.58+$195,412.724,484Direct
Mar 8, 2022Class A Common StockSSaleDisposed−4,484$72.00−$322,8480Direct
Mar 10, 2022Class A Common StockMOption exerciseAcquired+10,000$43.58+$435,80010,000Direct
Mar 10, 2022Class A Common StockSSaleDisposed−10,000$70.04F1−$700,4000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 8, 2022Class A Common StockMOption exerciseDisposed−4,484$0.00$020,516Direct
Mar 10, 2022Class A Common StockMOption exerciseDisposed−10,000$0.00$010,516Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.135, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)